Inactive Instrument

Forward Pharma A/S

Equities

FWPAY

US34986J3032

Biotechnology & Medical Research

Forward Pharma A/S Reports Earnings Results for the Full Year Ended December 31, 2020

April 14, 2021 at 04:19 pm EDT

Forward Pharma A/S announced earnings results for the full year ended December 31, 2020. For the full year, the company announced operating loss was USD 3.386 million compared to USD 5.283 million a year ago. Net loss was USD 6.449 million compared to USD 4.221 million a year ago. Basic loss per share from continuing operations was USD 0.07 compared to USD 0.04 a year ago.

Latest news about Forward Pharma A/S

Mason Capital Management LLC has commenced a tender offer to acquire Forward Pharma A/S for DKK 74.8 million.	May. 13	CI
China Reopening Prospects Lend Some Support to European Equities But Uncertain Outlook Weighs	22-12-28	MT
European Equities Broadly Flat Amid End of Chinese COVID-19 Quarantine Restrictions	22-12-27	MT
Forward Pharma A/S(OTCPK:FWPA.Y) dropped from NASDAQ Composite Index	22-12-27	CI
European Equities Rise Modestly in Friday Trading, End Week Up 1%	22-12-23	MT
European Equities Buoyed by Financial, Pharma Stocks in Tuesday Trading	22-12-20	MT
Top Midday Decliners	22-12-19	MT
European Equities Lose Early Momentum, Remain Relatively Flat in Monday Trading	22-12-19	MT
Forward Pharma Says it Expects to Be Delisted From Nasdaq; Shares Plunge	22-12-19	MT
Biotechnology Gains Lead European Equities Higher in Wednesday Trading	22-12-14	MT
European Equities Rise Modestly Friday, But End Week Lower	22-12-09	MT
European Equities Nudge Higher on Slightly Lower Euro Area Inflation	22-11-30	MT
Rising COVID Cases in China, Plunging Oil Prices Drag European Equities Lower in Monday Trading	22-11-21	MT
European Markets Move Higher Helped by Upbeat US Inflation Data	22-11-15	MT
European ADRs Continue to Trend Higher in Monday Trading	22-11-14	MT
European ADRs Surge Higher as Global Markets React to US Inflation Data	22-11-10	MT
Forward Pharma A/S Reports Earnings Results for the Half Year Ended June 30, 2022	22-11-09	CI
European ADRs Move Higher in Tuesday Trading, Adding to Monday's Gains	22-11-08	MT
European ADRs Move Lower in Monday Trading	22-10-31	MT
European ADRs Move Higher in Thursday Trading	22-10-27	MT
European ADRs Climb Sharply Higher in Monday Trading	22-10-17	MT
European ADRs Move Higher in Thursday Trading	22-10-13	MT
European ADRs Move Higher in Friday Trading	22-09-30	MT
European ADRs Move Lower in Wednesday Trading	22-09-21	MT
European ADRs Move Lower in Tuesday Trading	22-09-20	MT

Chart Forward Pharma A/S

Duration

Period

More charts

Company Profile

Forward Pharma A/S is a Denmark-based biopharmaceutical company, that commenced development in 2005 of a formulation of DMF for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The Company has the opportunity to receive royalties from Biogen on Biogen's net sales of Tecfidera or other DMF products for multiple sclerosis outside the U.S., dependent on, among other things, a favorable outcome in Europe with respect to the 355 Patent Opposition Proceeding, including any appeal thereto.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+18.15%	124B
REGENERON PHARMACEUTICALS, INC.	+18.02%	112B
ARGENX SE	+5.07%	22.94B
BIONTECH SE	-12.75%	22.22B
BEIGENE, LTD.	-9.86%	17.02B
GENMAB A/S	-14.97%	16.88B
WUXI APPTEC CO., LTD.	-39.94%	16.87B
NEUROCRINE BIOSCIENCES, INC.	+2.80%	13.63B
SAREPTA THERAPEUTICS, INC.	+27.39%	11.61B

Bio Therapeutic Drugs